Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis
Authors
Keywords
-
Journal
CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-15
DOI
10.1007/s10067-022-06329-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update
- (2022) Robert B M Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- GRAPPA Treatment Recommendations: 2021 Update
- (2022) Laura C. Coates et al. JOURNAL OF RHEUMATOLOGY
- Treatment of axial spondyloarthritis: an update
- (2022) Abhijeet Danve et al. Nature Reviews Rheumatology
- American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4
- (2022) Jeffrey R. Curtis et al. Arthritis & Rheumatology
- JAK inhibitors as a Barrier to the Destructive Cytokine Storm in COVID-19
- (2022) Ali Saeedi-Boroujeni et al. Current Drug Research Reviews
- Immunogenicity and Safety of SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases: A Systematic Review and Meta-analysis
- (2022) Akhil Sood et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
- (2021) Rita A. Moura et al. Frontiers in Medicine
- SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
- (2021) David Simon et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
- (2021) Ulf M Geisen et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
- (2021) Parakkal Deepak et al. ANNALS OF INTERNAL MEDICINE
- Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
- (2021) Marcia A Friedman et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
- (2021) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
- (2021) Anuraag Jena et al. AUTOIMMUNITY REVIEWS
- Reply
- (2021) Jeffrey R. Curtis et al. Arthritis & Rheumatology
- Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
- (2021) Sebastian Eduardo Sattui et al. RMD Open
- Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
- (2021) Laura Boekel et al. Lancet Rheumatology
- Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
- (2021) Féline P B Kroon et al. ANNALS OF THE RHEUMATIC DISEASES
- 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
- (2021) Alessia Alunno et al. ANNALS OF THE RHEUMATIC DISEASES
- Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases
- (2021) Narcis-George Manolache et al. JOURNAL OF INFECTION
- Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination
- (2021) Liat Iancovici et al. RHEUMATOLOGY
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
- (2018) Satoshi Kubo et al. Frontiers in Immunology
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
- (2015) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
- (2010) Richard J. Riese et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More